胰腺癌
癌症研究
淋巴系统
医学
转移
癌相关成纤维细胞
淋巴结
癌症
淋巴
癌细胞
淋巴结转移
氧化代谢
糖酵解
肿瘤微环境
生物
淋巴管新生
淋巴管内皮
新陈代谢
下调和上调
体内
临床试验
药品
上皮-间质转换
作者
Tianxing Zhou,Jingrui Yan,Guohua Mao,Yu Zhang,Shangheng Shi,Tinghai Hu,J Xu,Yaqi Zhang,Zhi Ji,Qingxiao Fang,Zhaoyu Zhang,Zekun Li,Ziyun Liu,Yifei Wang,Hongwei Wang,Tiansuo Zhao,Song Gao,Xiuchao Wang,Chao Yang,Chongbiao Huang
标识
DOI:10.1158/2159-8290.cd-25-1627
摘要
Lymph node metastasis (LNM) in early-stage PDAC predicts systemic dissemination and poor survival, yet its underlying mechanisms remain elusive. Here, we demonstrated that senescent cancer-associated fibroblasts (senCAFs) drive lymphatic remodeling and LNM in early-stage PDAC. Mechanistically, senCAFs increased glucose metabolism and lactate production, which activated lactylation-mediated serine metabolism to protect lymphatic endothelial cells from oxidative stress. Moreover, we discovered CCR4+ Tregs from the draining lymph nodes accumulated around lymphatic vessels, which established an immunosuppressive peri-lymphatic niche. High throughput drug screening determined selective clearance of senCAFs via chidamide, attenuated tumor progression and improved chemo-immunotherapeutic efficacy. We subsequently initiated a clinical trial (chidamide and nab-paclitaxel/gemcitabine plus anti-PD-1/CTLA-4) in metastatic PDAC patients and reported its preliminary promising results. Collectively, these findings reveal a closed link between cellular senescence and PDAC metastasis, offering the potential senolytic means to improve chemo-immunotherapy efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI